GlassScriptPhysician profile
James W Ervin
NPI 1619903580
$8,076.87
in general payments reported to CMS, 2019-2025
30 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,478 · 2020: $1,111 · 2021: $983 · 2022: $989 · 2023: $1,329 · 2024: $1,028 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,515.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,174.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $743.87 | 2019-2024 | Wegovy, Saxenda |
| Pfizer INC. | $650.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $613.28 | 2019-2025 | Trelegy Ellipta, Arexvy, Boostrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $592.56 | 2019-2025 | Jardiance |
| Amgen INC. | $552.22 | 2019-2025 | Evenity, Repatha, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $532.96 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $528.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $508.82 | 2019-2023 | Belsomra, Verquvo, Steglatro |
| Abbvie INC. | $498.01 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $326.45 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $280.08 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $193.12 | 2021-2024 | Xarelto |
| Idorsia Pharmaceuticals US INC | $126.58 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $110.74 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $96.95 | 2021-2024 | Keveyis |
| Genentech USA, INC. | $95.31 | 2019-2020 | |
| Exact Sciences Corporation | $86.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $45.68 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $44.80 | 2019-2021 | |
| Abbott Laboratories | $42.93 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $41.35 | 2024 | Voquezna |
| Amarin Pharma, INC. | $41.21 | 2019-2021 | |
| Boston Scientific Corporation | $31.03 | 2025 | Watchman Access System |
| Tris Pharma INC | $29.64 | 2023 | Dyanavel Xr |
| Inspire Medical Systems, INC. | $27.64 | 2025 | Inspire |
| Allergan, INC. | $23.97 | 2019 | |
| Sanofi Pasteur INC. | $13.25 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $12.99 | 2020 | |
| Nalpropion Pharmaceuticals LLC | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ervin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.